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Our study investigates the impact of the NLST publication in 2011 on the lung cancer
outcomes in the general US Population by assessing the incidence rates, ratio of
early/late stage, and lung cancer mortality in the years immediately prior to and
following this publication.
Lung cancer is the second most common cancer in both men and women, comprising
13% of all new cancers. It is by far the leading cause of cancer death among men and
women. Each year, more people die of lung cancer than of colon, breast, and prostate
cancers combined. Increasing age is a risk factor for the development of lung cancer
with most cases diagnosed in individuals who are 65 or older.(1,2) There is an
increasing effort to improve early detection of lung cancer, since this is a curable cancer
if diagnosis and treatment are performed in a timely manner.(3)
The National Lung Cancer Screening Trial (NLST) demonstrated improved overall
survival (OS) and lung cancer specific survival (LCSS), likely due to finding early-stage
Non-Small Cell Lung Cancer (NSCLC). (4,5)
Although the overall lung cancer rates remained stable during the study period, a
significant increase in the ratio of early/late stage was observed following the release of
NLST for the overall lung cancer population (p=0.006) and for the screening age group
(p= 0.014). The effects of ratio of early/late stage as noted in the overall group persisted
for all patient subgroups, except for patients associated with a median income
<$40,000, for those who were white, and for the following regions: Detroit Metro, Iowa,
Greater and Rural Georgia and Louisiana where no association was found between the
release of the NLST and changes in the ratios of early detection. Even more, in some
cases there was a decrease in late stage detection. There was no impact on lung
cancer mortality in the general lung cancer population or in any patient subgroups.
Since the publication of the NLST in 2011, there has been no impact on lung cancer
mortality or overall incidence of lung cancer in the general US population. However, there
is a favorable increase in the proportion of early stage lung cancers, depending upon
median family income, race and location. Our approach has limitations due the length of
time after trial release and recommendation by the US Preventive Services Task Force
(USPSTF) in 2015. We may see a further shift in the coming years because the US
Preventive Services Task Force (USPSTF) recommended screening and CMS approved
lung cancer CT-screening, both in 2015. We will develop further analysis and models to
expand the understanding of the impact of lung cancer screening in the upcoming years.
Rate sessions from the SEER18 database were accessed during the years 2008-2015.
We analyzed overall lung cancer incidence and mortality rates. The ratio of early/late
stage was obtained by dividing the number of stage I and II cases by the number of
stage III and IV diagnosed by year. We investigate changes in level and trend using
interrupted time series in STATA12, considering 2011 as the intervention. In addition,
we performed a T-test for averages ratios comparing the years 2007-2010 to the years
2012-2015 for the entire lung cancer population and for subgroups by median family
income, ethnicity, sex, age and SEER Registry.
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Figure 2. Early, Late stage lung Cancer rate 
*100.000 inhabitants and ratio Early/late 
stage SEER-18 registries, 2007 to 2015, 
United States.
Figure 4. Lung Cancer rate *100.000 inhabitants and ratio Early/late stage SEER-18 registries, 
by age groups, (A) 55-74 years old, (B) 75+ years old, 2007 to 2015, United States.
Figure 5. Lung Cancer rate *100.000 inhabitants 
and ratio Early/late stage SEER data base, by 
income, (A)< $40,000, (B) $40,000-<$75,000,  
(C) $75,000-99,000 and (D) $100,000 +  ,  2007 
to 2015, United States.
Figure 3. Lung Cancer rate *100.000 inhabitants and ratio Early/late stage SEER-18 registries, 
(A) male and (B) female, 2007 to 2015, United States.
Results
Figure 1. Overall Lung Cancer rate and 
mortality rates at 25 months and 36 months 
*100.000 inhabitants SEER-18 registries, 
2007 to 2015, United States.
The significance levels varied between  T-Test 
(p-value I) and Interrupted time series analysis 
(p-value II), being relevant to the age groups, 
and some geographic locations.
Table 1. Means ratio of early/late stage of 
Non-Small Cell Lung Cancer (NSCLC) for 
2007-2010 and 2012-2015, SEER-18 
registries.
Variables 2007-2010 2012-2015 p-value I* p-value II** 
Overall 0.37 0.39 0.026 0.006 
Male 0.34 0.35 0.101 0.011 
Female 0.41 0.44 0.009 0.003 
Non-Hispanic white 0.39 0.36 0.307 0.498 
Non-Hispanic black 0.28 0.31 0.011 0.036 
Hispanic 0.38 0.41 0.044 0.014 
Asian 0.31 0.34 0.021 0.393 
55-74 0.37 0.39 0.227 0.014 
75+ 0.41 0.46 0.004 0.798 
Low Income  0.35 0.33 0.250 0.365 
Median Income 0.35 0.38 0.024 0.033 
Median-high Income 0.39 0.43 0.029 0.002 
High Income 0.39 0.42 0.033 0.009 
Very High Income 0.42 0.47 0.043 0.046 
San Francisco 0.34 0.41 0.004 0.313 
Connecticut 0.44 0.50 0.018 0.015 
Detroit Metro 0.37 0.37 0.933 0.289 
Hawaii 0.33 0.35 0.379 0.020 
Iowa 0.37 0.36 0.888 0.215 
New Mexico 0.34 0.38 0.082 0.540 
Seattle 0.38 0.44 0.004 0.039 
Utah 0.31 0.35 0.019 0.217 
Atlanta Metro 0.35 0.38 0.389 0.487 
San Jose 0.36 0.40 0.108 0.354 
Los Angeles 0.33 0.37 0.014 0.446 
Alaska 0.24 0.32 0.291 0.254 
Georgia- Rural 0.38 0.32 0.227 0.284 
California-Others 0.36 0.40 0.053 0.455 
Kentucky 0.38 0.39 0.310 0.359 
Louisiana 0.35 0.35 0.872 0.738 
New Jersey 0.40 0.44 0.019 0.020 
Greater Georgia 0.37 0.36 0.393 0.488 
p‐value I* reflects a T‐test between the two periods, p‐value < 0.05 are in bold 
p‐value II**reflects the interrupted time series p‐value for the level estimate in the final models. 
 
